urocore.com
Apr 19, 2025, 06:03
Lars Dyrskjøt: Circulating tumour DNA and circulating tumour cells in bladder cancer
Lars Dyrskjøt, Professor at Aarhus University, shared on X:
“Our review “Circulating tumour DNA and circulating tumour cells in bladder cancer — from discovery to clinical implementation” is now out in Nature Reviews Urology
A tour de force by Sia Viborg Lindskrog and Trine Strandgaard – kudos and thanks to all co-authors for your contributions.
In the review, we discuss:
- The biology and detection of ctDNA and CTCs in bladder cancer
How liquid biopsy enables:
- Early detection of recurrence
- Monitoring of treatment response
- Detection of minimal residual disease (MRD)
- Personalized adjuvant treatment guidance
- The pros and cons of tumour-informed vs. tumour-agnostic strategies
- Insights from pivotal clinical trials (TOMBOLA, IMvigor011, MODERN) and their potential impact
- The road to clinical implementation: technical, logistical, and regulatory considerations
- The combined value of ctDNA, utDNA, and CTCs in reshaping the bladder cancer care pathway
Why it matters:
Liquid biopsy is moving from promise to practice — with real potential to personalize and improve bladder cancer treatment.”
“Circulating tumour DNA and circulating tumour cells in bladder cancer — from discovery to clinical implementation”
Authors: Sia V. Lindskrog, Trine Strandgaard, Iver Nordentoft, Matthew D. Galsky, Thomas Powles, Mads Agerbæk, Jørgen Bjerggaard Jensen, Catherine Alix-Panabières, Lars Dyrskjøt
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 19, 2025, 13:43
Apr 19, 2025, 13:05